HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oréal appointments

This article was originally published in The Rose Sheet

Executive Summary

Kelly McNamara is promoted to VP, public relations for Giorgio Armani Parfums and Cosmetics, L'Oréal USA Luxury Products division reports May 23. McNamara joined L'Oréal in 1997 to lead public relations for the European Designer Fragrances division, and later assumed responsibility for Giorgio Armani. Exec's efforts have been "instrumental in the growth of the brand's fragrance business and essential in the successful launch of cosmetics starting in 2001," according to L'Oréal. Separately, Biotherm USA's newly appointed General Manager Catherine Roggero will be tasked to "build the momentum of Biotherm's presence in the U.S.," according to the firm. Effective June 1, exec succeeds Chris Harrison, who was appointed general manager of military sales for L'Oréal USA Luxury Products Division. Roggero has worked at L'Oréal for more than eight years, serving most recently as VP of international development for Kiehl's Since 1851, where she led the launch of the brand in markets outside the U.S., firm notes...

You may also be interested in...



Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel